systematic_review
    2020
    High Quality

    Omega-3 fatty acids for cardiovascular disease prevention

    Abdelhamid, A.S., Brown, T.J., Brainard, J.S.

    Published in Cochrane Database

    Abstract

    Omega-3 fatty acid supplementation may reduce cardiovascular disease risk and mortality.

    Methodology

    Cochrane systematic review and meta-analysis of 86 randomised controlled trials (about 162,800 participants) of increased long-chain omega-3, alpha-linolenic acid or total polyunsaturated fat intake versus usual intake, with GRADE assessment of mortality and cardiovascular outcomes.

    Key Findings

    Increasing long-chain omega-3 intake had little or no effect on all-cause mortality, cardiovascular mortality, coronary events or stroke (moderate to high certainty). Small reductions in coronary heart disease mortality and events were possible but of low certainty. Triglycerides fell dose-dependently by roughly 15% and HDL rose slightly. Trials used doses mostly between 0.5 and 5 g daily over one to six years.

    Conclusions

    Routine omega-3 supplementation does not meaningfully reduce cardiovascular mortality or events in the general population; its clearest use is triglyceride lowering rather than broad cardiovascular prevention.

    Limitations

    Marked heterogeneity in dose, formulation, duration and background diet; many older trials predate statin-era care; participants were largely at moderate rather than very high risk, and adherence and background fish intake were variably reported.

    Supplements Studied

    Increasing EPA and DHA has little or no effect on all-cause mortality and cardiovascular events.

    Outcomes Measured

    Increasing EPA and DHA has little or no effect on all-cause mortality and cardiovascular events.

    Long-chain omega-3 supplementation slightly reduced triglycerides in a dose-dependent manner.

    Increasing long-chain omega-3 intake had little or no effect on all-cause mortality, cardiovascular mortality, coronary events or stroke (moderate to high certainty). Small reductions in coronary heart disease mortality and events were possible but of low certainty. Triglycerides fell dose-dependently by roughly 15% and HDL rose slightly. Trials used doses mostly between 0.5 and 5 g daily over one to six years.

    Related Health Concerns

    Study Details

    Year:2020
    Sample Size:162,796
    Quality Score:10/10

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.